http://www.slideshare.net/mkdas_ongc/group-7-sdm-kramer-pharmaceuticals * 1. Case Study Kramer Pharmaceuticals, Inc. Presented by Debi Prasad Bagria Kishor Chandwani Nandini Mudgil Mrinmoy Kanti Das Rahul Agarwal Ritesh Kumar Singh * 2. Case Background Company : Kramer Pharmaceuticals, Inc Business : Pharmaceuticals (Manufacturer of Prescription Drugs) Country : U.S. Year : 1978 Competitors: Abbott, Lilly, Merck, Upjohn & Schering * 3. Case Background Bob Marsh, a former detailer, worked at Kramer Pharmaceutical for 12 years and was considered a hard working, well established detailer (product specialist and sales associate). He possessed excellent references and credentials. Bob was fired because of failure to comply with …show more content…
* 13. Bob Marsh – Performance over the years Rehabilitation blueprint of Marsh by Franlin & new Zone Manager Pete Mallick – Weekly reports, reading assignments, questionnaire forms. July’78 – At age 44 years, Marsh asked to resign which he accepted without resistance or comment ’ 78 Tom Franklin (Young – one year supervisory experience) No salary increase in Jan’78 But Probation status evaporated by default Sept’76 to ’78 Tom Wilkens (Background comparable to Reed) In ’77 : Initially recommended for salary hike, but later rated Complete unsatisfactory : Again put on probation of 90 days Aug’76 to Sept’77 Vince Reed (Young, Competent Detailer & Promising Manager - 1 st supervisory experience) No Salary Increase in Jan’75 : Put on probation of 90 days Probation removed : Performance found Satisfactory In Jan’76 : Salary Increased to $25k Sept’74 to Aug’76 Jim Rathbun (Bright, young, energetic with many new ideas) In ’71 – 73 : Performance Rating Satisfactory In ’74 : Performance : Well above average Attitude : Well above average March’71 to Sept’74 Bill Couch Experienced & Highly regarded supervisor) in ’67 & ’68 Work Performance : Below Standard Attitude : Standard In ’69 : Overall performance : Standard In ’70 : Rated Completely satisfactory From ‘66 to March’71 John Meredith (Took entry interview of Bob, highly recommended him) Observations Period Supervisor * 14. Bob Marsh – In the eyes of Supervisors Quickly grasped all
The competitors were the local fertility clinics. The largest clinic had eight doctors and took 5% market shares. Some of the clinics were able to similar services to Extend Fertility but were at the disadvantage to the company. The firm was the only one got FDA proved
The case consists of two major pharmaceutical companies that joint to collaborate their research and pharmaceutical technologies to start a joint venture in India. Both have valuable resources that have benefited both companies during the joint venture. Now both are questioning if there is still any value in maintaining the joint venture in India and will be deciding what will be the best route to take. Ranbaxy Laboratories wants to be bought out, but Eli Lilly is worried of the financial implications of such move.
Those target markets who rely on Johnson & Johnson health and medical needs are mostly patients, doctors, nurses and civilians. Therefore, the company need to sustain their products and services over all these years to ensure that lower income people and underprivileged patients are able to access on their medicines. This however requires the company to balance patient’s access and competitive dynamics in line with their need as the company need to have enough resources to keep on being innovating, creating new and better medicines and at the same time making sure there will be a fair return to the shareholder as well. Johnson & Johnson also work closely with the governments, physicians, non-government organizations and the international donors all around the world to provide its products within an affordable prices to its
Based on what you know so far, evaluate the Brooks approach to workforce reduction? What did Brooks do right and what did they do
U.S. based companies hold rights to most of the world’s rights on new medicines and holds thousands of new products currently being developed. As of 2012, the industry helps support almost 3.4 million jobs in the U.S. economy. It is also one of the most heavily R&D based industries in the world. In the United States, the environment for pharmaceuticals is much friendlier than other countries around the world in terms of pricing ability and regulations. Both the Pharmaceutical and Biotechnology industries have experienced significant growth in the past year with year-over-year increases of 13.02% and 34.69% respectively. It is an even more striking when looking at the past five years considering both have beat out the S&P 500 with pharmaceuticals increasing an additional 31.44% and the biotechnology sector besting an astonishing 269.3% more return than the
Pfizer is the largest American pharmaceutical company and one of the largest pharmaceutical companies in the world. It competes with Merck and Glaxo, and markets such well-known medications as Celebrex and Viagra. However, the pharmaceutical industry as a whole has undergone changes in recent years with significant consolidation taking place and with increased scrutiny regarding the ways in which drugs are developed, tested and marketed. In addition, recent controversies have erupted regarding Merck's drug Vioxx, and Pfizer has been the target of unwanted publicity regarding its painkiller Celebrex. This research considers the strategic position of Pfizer, including its strengths and weaknesses as well
Five of the top ten pharmaceutical companies are located in the United States and the other five are European companies, all of these companies combined, employ approximately 787,000 people. The ranking of the following pharmaceutical companies are based on
There are advantages of starting a pharmaceutical firm in India. It has emerged from being an enzyme-producing firm to a biotech powerhouse under the guidance of Ms Kiran M. Shaw. They have a well-established pharmaceutical industry that has been growing since 1947. After the purchase of Hindustan Antibiotics Ltd. and India Drug and Pharmaceuticals Ltd. they were able to compete with the MNC’s (Multi National Corporaton) from overseas (Kalegaonkar, Locke, Lehrich, 2008, p. 2). In the beginning the pharmaceutical industry saw substantial growth. “By the beginning of the 21st century, over 20,000 pharmaceutical companies were operating in India” (Kalegaonkar, Locke, Lehrich, 2008, p. 2). “The pharmaceutical industry in India is ranked third
Eli Lilly was approached by a leading pharmaceutical firm in India to consider building a joint venture together. Ranbaxy Laboratories began as a family business in the 1960’s, but with strong entrepreneurial skills the company grew to become one of the largest manufacturers for bulk drugs and generic drugs. The two companies considered pursuing a joint venture that would support on another’s products by supplying one other with ingredients to complete company products without having to trade with other companies internationally. The JV would potentially lead both companies, together to become a dominant force in the Indian market.
We analyzed the Indian Pharmaceutical industry on these five forces and the findings of industry competitiveness and profitability are written under the relevant competitive forces.
I see the problem as this: A blatant disrespect displayed by a few of the managers, specifically the most recent Mr. Franklin who was the manager in charge of Marsh when he was asked to resign. Franklin constantly hounded Marsh, saying that he portrayed poor work habits and was disorganized and
Merck was established in 1891 to improve human and animal health through the development of innovative products. Merck currently has two reportable segments, the Pharmaceutical Segment and the Vaccines and Infectious Diseases Segment. Merck sells products through several channels including wholesalers, retailers, hospitals, clinics, government and managed health services providers. In the 1980’s the Merck was very successful in producing 10 major new drugs and had a very healthy pipeline. In later years, Merck has entered into joint ventures with many other pharmaceutical companies in order to expand its pipeline. In the last several years Merck has
Pfizer Inc is a multinational investment company. It ventures in the medical and pharmaceutical industry. It is renowned as a giant pharmaceutical company, founded in 1849. It is based in the United States, New York, Manhattan at Midtown. It is the largest universal producer and trader of pharmaceuticals (Turner, 2005, pg 161). Some of the products availed to the market by the company are Lipitor, Lyrica, Diflucan, Zithromax, Zoloft, Viagra and Celebrex. These products are targeted to patients and persons in need of enhancements in their body systems and anatomy. It has an employee capacity of 12000 people in all its departmental sectors and sub-branches. The sub-branches are distributed all over and in all continents (Turner, 2005, pg 163).
activities and tactics such as sampling and sales force promotion [3]. Whether a brand manager is using right promotional tools, whether 4P`s (now 7P`s are considered) are linked to each other and with product strategies for the two main objectives that includes [3]: To Generate Prescription Make the product reach the patient They can be said as Product chain and Prescription chain 1.1 The Product Chin This starts from selection of molecules and ends in the hands of patient. This chain is somehow intensive as it starts from the selection of molecules, then molecules are critically screened, after the screening of molecules the source of raw material is identified then the pilot batch manufacturing process starts at this stage pricing strategies and clinical trials are worked out. Once the pilot batch is manufactured then it starts with the commercialization of product, after commercialization product goes to distribution house and then it reaches the retailers. After patient’s diagnosis by doctor, patient purchases that product from retailer [4]. 1.2